MiR-205-5p Downregulation and Upregulation Characterize the Disseminated Tumor Cells in Patients with Invasive Ductal Breast Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jan 11

PMID 35008529

Authors

Lenka Kalinkova

Nataliia Nikolaieva

Bozena Smolkova

Sona Ciernikova

Karol Kajo

Vladimir Bella

Viera Horvathova Kajabova

Helena Kosnacova

Gabriel Minarik

Ivana Fridrichova

Affiliations

Soon will be listed here.

Abstract

Background: Dissemination of breast cancer (BC) cells through the hematogenous or lymphogenous vessels leads to metastatic disease in one-third of BC patients. Therefore, we investigated the new prognostic features for invasion and metastasis.

Methods: We evaluated the expression of miRNAs and epithelial-to-mesenchymal transition (EMT) genes in relation to /E-cadherin changes in samples from 31 patients with invasive ductal BC including tumor centrum (TU-C), tumor invasive front (TU-IF), lymph node metastasis (LNM), and CD45-depleted blood (CD45-DB). Expression of miRNA and mRNA was quantified by RT-PCR arrays and associations with clinico-pathological characteristics were statistically evaluated by univariate and multivariate analysis.

Results: We did not verify regulating associations previously described in cell lines. However, we did detect extremely high expression in LNMs from patients with distant metastasis, but without regulation by miR-205-5p. Considering the ZEB1 functions, this overexpression indicates enhancement of metastatic potential of lymphogenously disseminated BC cells. In CD45-DB samples, downregulated miR-205-5p was found in those expressing epithelial and/or mesenchymal markers (CTC+) that could contribute to insusceptibility and survival of hematogenously disseminated BC cells mediated by increased expression of several targets including .

Conclusions: miR-205-5p and potentially gene are promising candidates for markers of metastatic potential in ductal BC.

Citing Articles

Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments.

Qiu J, Qian D, Jiang Y, Meng L, Huang L Front Oncol. 2023; 13:1288077.

PMID: 37941557 PMC: 10628786. DOI: 10.3389/fonc.2023.1288077.

Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis.

Frisk N, Sorensen A, Pedersen O, Dalgaard L Biomolecules. 2023; 13(5).

PMID: 37238740 PMC: 10216356. DOI: 10.3390/biom13050871.

The Metastatic Process through the Eyes of Epigenetic Regulation: A Promising Horizon for Cancer Therapy.

Smolkova B, Earl J, Kataki A Int J Mol Sci. 2022; 23(24).

PMID: 36555088 PMC: 9778637. DOI: 10.3390/ijms232415446.

Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?.

Fridrichova I, Kalinkova L, Ciernikova S Int J Mol Sci. 2022; 23(20).

PMID: 36292996 PMC: 9603393. DOI: 10.3390/ijms232012141.

miRNA in Molecular Diagnostics.

Matulic M, Grskovic P, Petrovic A, Begic V, Harabajsa S, Korac P Bioengineering (Basel). 2022; 9(9).

PMID: 36135005 PMC: 9495386. DOI: 10.3390/bioengineering9090459.

References

Hu Y, Qiu Y, Yague E, Ji W, Liu J, Zhang J . miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 2016; 7(6):e2291. PMC: 5108343. DOI: 10.1038/cddis.2016.194. View

Eng L, Dawood S, Sopik V, Haaland B, Tan P, Bhoo-Pathy N . Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016; 160(1):145-152. DOI: 10.1007/s10549-016-3974-x. View

Zhou X, Marian C, Makambi K, Kosti O, Kallakury B, Loffredo C . MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One. 2012; 7(6):e39011. PMC: 3377597. DOI: 10.1371/journal.pone.0039011. View

Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z . Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells. Genes Cancer. 2012; 2(8):782-91. PMC: 3278899. DOI: 10.1177/1947601911429743. View

Wu H, Zhong H, Li G, Shen J, Ye Q, Zhang M . Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med. 2020; 18(1):51. PMC: 6998212. DOI: 10.1186/s12967-020-02240-z. View

Cierna Z, Mego M, Janega P, Karaba M, Minarik G, Benca J . Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer. 2014; 14:472. PMC: 4079912. DOI: 10.1186/1471-2407-14-472. View

Wong S, Hynes R . Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide?. Cell Cycle. 2006; 5(8):812-7. PMC: 1459485. DOI: 10.4161/cc.5.8.2646. View

Cai K, Feng C, Zhao J, He R, Ma J, Zhong J . Upregulated miR‑203a‑3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta‑analysis. Mol Med Rep. 2018; 18(6):4994-5008. PMC: 6236224. DOI: 10.3892/mmr.2018.9543. View

Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V . RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark. 2012; 10(1):13-26. DOI: 10.3233/CBM-2012-0230. View

10.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

11.

Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

12.

Bidard F, Proudhon C, Pierga J . Circulating tumor cells in breast cancer. Mol Oncol. 2016; 10(3):418-30. PMC: 5528978. DOI: 10.1016/j.molonc.2016.01.001. View

13.

Xiao Y, Humphries B, Yang C, Wang Z . MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. Noncoding RNA. 2019; 5(4). PMC: 6958506. DOI: 10.3390/ncrna5040053. View

14.

Moyret-Lalle C, Ruiz E, Puisieux A . Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer. World J Clin Oncol. 2014; 5(3):311-22. PMC: 4127603. DOI: 10.5306/wjco.v5.i3.311. View

15.

Borcherding N, Cole K, Kluz P, Jorgensen M, Kolb R, Bellizzi A . Re-Evaluating E-Cadherin and β-Catenin: A Pan-Cancer Proteomic Approach with an Emphasis on Breast Cancer. Am J Pathol. 2018; 188(8):1910-1920. PMC: 6119824. DOI: 10.1016/j.ajpath.2018.05.003. View

16.

Lee J, Park M, Park J, Lee H, Shin D, Kang Y . Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene. 2013; 33(10):1325-35. DOI: 10.1038/onc.2013.53. View

17.

Sleeman J, Nazarenko I, Thiele W . Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011; 128(11):2511-26. DOI: 10.1002/ijc.26027. View

18.

Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y . Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014; 16(2):R23. PMC: 4053256. DOI: 10.1186/bcr3622. View

19.

Cummings M, Simpson P, Reid L, Jayanthan J, Skerman J, Song S . Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2013; 232(1):23-31. PMC: 4288974. DOI: 10.1002/path.4288. View

20.

Lv X, Jiao Y, Qing Y, Hu H, Cui X, Lin T . miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer. 2011; 30(12):821-30. PMC: 4013330. DOI: 10.5732/cjc.011.10289. View